Table 3.
Quantitative MBF in patients treated with CTO PCI vs non‐CTO PCI
| CTO (n = 92) | Non‐CTO (n = 31) | P value | |
|---|---|---|---|
| Rest MBF pre‐PCI | 0.86 ± 0.25 | 0.83 ± 0.15 | 0.52 |
| Rest MBF post‐PCI | 0.86 ± 0.22 | 0.97 ± 0.29 | 0.03 |
| P value | 0.95 | <0.01 | |
| Δ rest MBF | 0.00 ± 0.23 | 0.13 ± 0.23 | <0.01 |
| Hyperemic MBF pre‐PCI | 1.30 ± 0.37 | 1.58 ± 0.62 | <0.01 |
| Hyperemic MBF post‐PCI | 2.48 ± 0.73 | 2.89 ± 0.94 | 0.03 |
| P value | <0.01 | <0.01 | |
| Δ hyperemic MBF | 1.18 ± 0.68 | 1.31 ± 1.07 | 0.57 |
| CFR pre‐PCI | 1.66 ± 0.75 | 1.89 ± 0.77 | 0.17 |
| CFR post‐PCI | 3.03 ± 1.05 | 3.10 ± 0.79 | 0.94 |
| P value | <0.01 | <0.01 | |
| Δ CFR | 1.37 ± 1.12 | 1.21 ± 0.97 | 0.35 |
Values are mean ± SD. MBF per mL·min−1·g−1. Outcomes are calculated using a linear regression analysis adjusted for age and gender.Abbreviations: Δ, change in MBF; CFR, coronary flow reserve; CTO, chronic coronary total occlusion; MBF, myocardial blood flow; PCI, percutaneous coronary intervention.